{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:46:23Z","timestamp":1786121183001,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Adoptive cellular therapies may expand treatment options for pediatric brain tumors by focusing activity on tumor antigens and limiting off-tumor effects. We systematically reviewed preclinical and clinical evidence for CAR T cells, TCR-engineered T cells, and NK or \u03b3\u03b4 T-cell platforms directed against HER2, B7-H3 (CD276), EGFR806-reactive EGFR, GD2, IL13R\u03b12, and EphA2 or EphA3, with attention to delivery route, safety, persistence, and combination strategies.\u00a0Following PRISMA, we searched PubMed, Embase, and Scopus from inception through September 17, 2025, restricted to English. The search yielded 324 records; 103 duplicates were removed; 221 titles and abstracts were screened; 180 full texts were reviewed; and 34 studies were extracted by two independent reviewers. We captured design, tumor and molecular features, product engineering, route and schedule, lymphodepletion, toxicities including cytokine release syndrome, immune effector cell associated neurotoxicity, and tumor inflammation associated neurotoxicity, radiographic or clinical response, survival, and correlatives such as persistence or trafficking in blood, cerebrospinal fluid, or tumor tissue, cytokines, and antigen dynamics.\u00a0In vivo studies showed reproducible antitumor activity for HER2 in medulloblastoma, GD2 in diffuse midline glioma, and multi-antigen constructs incorporating IL13R\u03b12 and EphA2 in medulloblastoma and ependymoma, with significant survival advantages compared with controls. \u03b3\u03b4 T cells targeting the EphA axis selectively killed medulloblastoma with neural sparing; GD2 CAR NK-92 inhibited diffuse intrinsic pontine glioma growth. In early clinical programs, route shaped safety and pharmacodynamics. For GD2, low-dose intravenous induction followed by repeated intraventricular dosing produced objective radiographic regressions and manageable tumor inflammation associated neurotoxicity, while dose-limiting cytokine release syndrome was confined to higher intravenous doses. Intraventricular B7-H3 CAR T cells, given without lymphodepletion, enabled multi-cycle dosing with mainly grade 1 to 2 events and cerebrospinal fluid localized persistence. Weekly intracranial EGFR806 CAR T cells were feasible and well tolerated, with stable disease as the best response in a small cohort. Across trials, persistence and immune activation were most evident in cerebrospinal fluid, supporting cerebrospinal fluid centered pharmacodynamic monitoring. Mechanism-based combinations, including IGF-axis inhibition in diffuse midline glioma and epigenetic priming of GD2 with an integrated safety switch in medulloblastoma, enhanced activity. The evidence supports pediatric-centric antigen selection and a CNS-first, locoregional dosing approach to increase on-tumor exposure and reduce systemic toxicity. Priorities include multi-antigen strategies to prevent escape, incorporation of safety switches, earlier deployment when tumor burden is low, and prospective cerebrospinal fluid pharmacodynamics in multisite phase II studies.<\/jats:p>","DOI":"10.1007\/s10143-026-04437-0","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:32:28Z","timestamp":1786073548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Locoregional and systemic adoptive cellular therapies for pediatric brain tumors: a systematic review of CAR\u2011T, TCR\u2011engineered T cells, and NK cell strategies"],"prefix":"10.1007","volume":"49","author":[{"given":"Yaxel Levin","family":"Carrion","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayant","family":"Bhasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sraavya","family":"Anne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Sawhney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caryn J.","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibraheem","family":"Sharaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Titkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvens","family":"Jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Pando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nemanja","family":"Novakovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal S.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morana","family":"Vojnic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"Suppl 3","key":"4437_CR1","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noac161","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom QT, Price M, Ryan K et al (2022) CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014\u20132018. Neuro-Oncol 24(Suppl 3):iii1\u2013iii38. https:\/\/doi.org\/10.1093\/neuonc\/noac161","journal-title":"Neuro-Oncol"},{"issue":"1","key":"4437_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/neuonc\/noad195","volume":"26","author":"J Fangusaro","year":"2024","unstructured":"Fangusaro J, Jones DT, Packer RJ et al (2024) Pediatric low-grade glioma: State-of-the-art and ongoing challenges. Neuro-Oncol 26(1):25\u201337. https:\/\/doi.org\/10.1093\/neuonc\/noad195","journal-title":"Neuro-Oncol"},{"issue":"3","key":"4437_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18(3):170\u2013186. https:\/\/doi.org\/10.1038\/s41571-020-00447-z","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"4437_CR4","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","volume":"389","author":"E Bouffet","year":"2023","unstructured":"Bouffet E, Hansford JR, Garr\u00e8 ML et al (2023) Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med 389(12):1108\u20131120. https:\/\/doi.org\/10.1056\/NEJMoa2303815","journal-title":"N Engl J Med"},{"issue":"8","key":"4437_CR5","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","volume":"3","author":"N Ahmed","year":"2017","unstructured":"Ahmed N, Brawley V, Hegde M et al (2017) HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol 3(8):1094\u20131101. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0184","journal-title":"JAMA Oncol"},{"key":"4437_CR6","doi-asserted-by":"publisher","unstructured":"Gust J, Cole BL, Ronsley R et al\u00a0Locoregional Infusion of EGFR806-CAR T Cells for Recurrent or Refractory Pediatric CNS Tumors: Results of the Completed BrainChild02 Phase 1 Clinical Trial. Neuro-Oncol. Published online March 12, 2025:noaf064.\u00a0https:\/\/doi.org\/10.1093\/neuonc\/noaf064","DOI":"10.1093\/neuonc\/noaf064"},{"issue":"1","key":"4437_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","volume":"13","author":"NA Vitanza","year":"2023","unstructured":"Vitanza NA, Wilson AL, Huang W et al (2023) Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety. Cancer Discov 13(1):114\u2013131. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0750","journal-title":"Cancer Discov"},{"issue":"8046","key":"4437_CR8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje M, Mahdi J, Majzner R et al (2025) Intravenous and intracranial GD2-CAR T cells for H3K27M(+) diffuse midline gliomas. Nature 637(8046):708\u2013715. https:\/\/doi.org\/10.1038\/s41586-024-08171-9","journal-title":"Nature"},{"key":"4437_CR9","doi-asserted-by":"publisher","unstructured":"Lertsumitkul L, Iliopoulos M, Wang SS et al (2024) EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses. J Immunother Cancer 12(8). https:\/\/doi.org\/10.1136\/jitc-2024-009486","DOI":"10.1136\/jitc-2024-009486"},{"issue":"1","key":"4437_CR10","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2485535","volume":"14","author":"L Boutin","year":"2025","unstructured":"Boutin L, Liu M, D\u00e9chanet Merville J, Bedoya-Reina O, Wilhelm MT (2025) EphA2 and phosphoantigen-mediated selective killing of medulloblastoma by \u03b3\u03b4T cells preserves neuronal and stem cell integrity. Oncoimmunology 14(1):2485535. https:\/\/doi.org\/10.1080\/2162402X.2025.2485535","journal-title":"Oncoimmunology"},{"issue":"12","key":"4437_CR11","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.7150\/ijbs.85813","volume":"19","author":"X Guo","year":"2023","unstructured":"Guo X, Chang M, Wang Y, Xing B, Ma W (2023) B7-H3 in Brain Malignancies: Immunology and Immunotherapy. Int J Biol Sci 19(12):3762\u20133780. https:\/\/doi.org\/10.7150\/ijbs.85813","journal-title":"Int J Biol Sci"},{"issue":"1","key":"4437_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40478-025-01991-4","volume":"13","author":"M Seblani","year":"2025","unstructured":"Seblani M, Zannikou M, Duffy JT et al (2025) IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas. Acta Neuropathol Commun 13(1):69. https:\/\/doi.org\/10.1186\/s40478-025-01991-4","journal-title":"Acta Neuropathol Commun"},{"key":"4437_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01582","volume":"10","author":"JD Patterson","year":"2020","unstructured":"Patterson JD, Henson JC, Breese RO, Bielamowicz KJ, Rodriguez A (2020) CAR T cell therapy for pediatric brain tumors. Front Oncol 10:1582. https:\/\/doi.org\/10.3389\/fonc.2020.01582","journal-title":"Front Oncol"},{"key":"4437_CR14","doi-asserted-by":"publisher","unstructured":"Miguel Llordes G, Medina P\u00e9rez VM, Curto Sim\u00f3n B, Castells-Yus I, V\u00e1zquez Sufuentes S, Schuhmacher AJ, Epidemiology (2023) Diagnostic Strategies, and Therapeutic Advances in Diffuse Midline Glioma. J Clin Med 12(16). https:\/\/doi.org\/10.3390\/jcm12165261","DOI":"10.3390\/jcm12165261"},{"key":"4437_CR15","doi-asserted-by":"publisher","unstructured":"Foster JB, Madsen PJ, Harvey K et al\u00a0Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high grade glioma models. Neuro-Oncol. Published online May 24, 2025:noaf115. https:\/\/doi.org\/10.1093\/neuonc\/noaf115","DOI":"10.1093\/neuonc\/noaf115"},{"issue":"3","key":"4437_CR16","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","volume":"31","author":"NA Vitanza","year":"2025","unstructured":"Vitanza NA, Ronsley R, Choe M et al (2025) Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat Med 31(3):861\u2013868. https:\/\/doi.org\/10.1038\/s41591-024-03451-3","journal-title":"Nat Med"},{"key":"4437_CR17","doi-asserted-by":"publisher","first-page":"100870","DOI":"10.1016\/j.neo.2022.100870","volume":"36","author":"NA Vitanza","year":"2023","unstructured":"Vitanza NA, Ronsley R, Choe M et al (2023) Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety. Neoplasia N Y N 36:100870. https:\/\/doi.org\/10.1016\/j.neo.2022.100870","journal-title":"Neoplasia N Y N"},{"issue":"12","key":"4437_CR18","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1158\/0008-5472.CAN-06-4309","volume":"67","author":"N Ahmed","year":"2007","unstructured":"Ahmed N, Ratnayake M, Savoldo B et al (2007) Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res 67(12):5957\u20135964. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4309","journal-title":"Cancer Res"},{"issue":"1","key":"4437_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40425-018-0340-z","volume":"6","author":"A Nellan","year":"2018","unstructured":"Nellan A, Rota C, Majzner R et al (2018) Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer 6(1):30. https:\/\/doi.org\/10.1186\/s40425-018-0340-z","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4437_CR20","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","volume":"24","author":"CW Mount","year":"2018","unstructured":"Mount CW, Majzner RG, Sundaresh S et al (2018) Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas. Nat Med 24(5):572\u2013579. https:\/\/doi.org\/10.1038\/s41591-018-0006-x","journal-title":"Nat Med"},{"issue":"7903","key":"4437_CR21","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner RG, Ramakrishna S, Yeom KW et al (2022) GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603(7903):934\u2013941. https:\/\/doi.org\/10.1038\/s41586-022-04489-4","journal-title":"Nature"},{"issue":"7","key":"4437_CR22","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/neuonc\/noaf095","volume":"27","author":"MEG Kranendonk","year":"2025","unstructured":"Kranendonk MEG, Hoogendijk R, Lammers JAS et al (2025) Do we need B7-H3 immunohistochemistry for the inclusion of children with high-grade central nervous system tumors in clinical trials targeting B7-H3? Neuro-Oncol 27(7):1864\u20131877. https:\/\/doi.org\/10.1093\/neuonc\/noaf095","journal-title":"Neuro-Oncol"},{"issue":"4","key":"4437_CR23","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s13760-024-02519-8","volume":"124","author":"AK Das","year":"2024","unstructured":"Das AK, Sinha M, Singh SK et al (2024) CAR T-cell therapy: a potential treatment strategy for pediatric midline gliomas. Acta Neurol Belg 124(4):1251\u20131261. https:\/\/doi.org\/10.1007\/s13760-024-02519-8","journal-title":"Acta Neurol Belg"},{"key":"4437_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1192448","volume":"13","author":"K Pandey","year":"2023","unstructured":"Pandey K, Wang SS, Mifsud NA et al (2023) A combined immunopeptidomics, proteomics, and cell surface proteomics approach to identify immunotherapy targets for diffuse intrinsic pontine glioma. Front Oncol 13:1192448. https:\/\/doi.org\/10.3389\/fonc.2023.1192448","journal-title":"Front Oncol"},{"key":"4437_CR25","doi-asserted-by":"publisher","unstructured":"Ferreras C, Fern\u00e1ndez L, Clares-Villa L et al (2021) Facing CAR T Cell Challenges on the Deadliest Paediatric Brain Tumours. Cells 10(11). https:\/\/doi.org\/10.3390\/cells10112940","DOI":"10.3390\/cells10112940"},{"key":"4437_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867154","volume":"13","author":"L Antonucci","year":"2022","unstructured":"Antonucci L, Canciani G, Mastronuzzi A, Carai A, Del Baldo G, Del Bufalo F (2022) CAR-T therapy for pediatric high-grade gliomas: peculiarities, current investigations and future strategies. Front Immunol 13:867154. https:\/\/doi.org\/10.3389\/fimmu.2022.867154","journal-title":"Front Immunol"},{"issue":"10","key":"4437_CR27","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.trecan.2023.07.007","volume":"9","author":"BC Thomas","year":"2023","unstructured":"Thomas BC, Staudt DE, Douglas AM, Monje M, Vitanza NA, Dun MD (2023) CAR T cell therapies for diffuse midline glioma. Trends Cancer 9(10):791\u2013804. https:\/\/doi.org\/10.1016\/j.trecan.2023.07.007","journal-title":"Trends Cancer"},{"issue":"9","key":"4437_CR28","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","volume":"27","author":"NA Vitanza","year":"2021","unstructured":"Vitanza NA, Johnson AJ, Wilson AL et al (2021) Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat Med 27(9):1544\u20131552. https:\/\/doi.org\/10.1038\/s41591-021-01404-8","journal-title":"Nat Med"},{"issue":"1","key":"4437_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad024","volume":"5","author":"SS Wang","year":"2023","unstructured":"Wang SS, Davenport AJ, Iliopoulos M et al (2023) HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma. Neurooncol Adv 5(1):vdad024. https:\/\/doi.org\/10.1093\/noajnl\/vdad024","journal-title":"Neurooncol Adv"},{"issue":"7","key":"4437_CR30","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/neuonc\/noab300","volume":"24","author":"E de Billy","year":"2022","unstructured":"de Billy E, Pellegrino M, Orlando D et al (2022) Dual IGF1R\/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant. Neuro-oncology 24(7):1150\u20131163. https:\/\/doi.org\/10.1093\/neuonc\/noab300","journal-title":"Neuro-oncology"},{"issue":"17","key":"4437_CR31","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1158\/1078-0432.CCR-24-3083","volume":"31","author":"S Mehta","year":"2025","unstructured":"Mehta S, Ippagunta S, Varadharajan S et al (2025) B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response. Clin Cancer Res Off J Am Assoc Cancer Res 31(17):3754\u20133770. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3083","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"5","key":"4437_CR32","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41591-020-0827-2","volume":"26","author":"LK Donovan","year":"2020","unstructured":"Donovan LK, Delaidelli A, Joseph SK et al (2020) Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med 26(5):720\u2013731. https:\/\/doi.org\/10.1038\/s41591-020-0827-2","journal-title":"Nat Med"},{"key":"4437_CR33","doi-asserted-by":"publisher","unstructured":"Bonada M, Pittarello M, De Fazio E et al (2024) Pediatric Hemispheric High-Grade Gliomas and H3.3-G34 Mutation: A Review of the Literature on Biological Features and New Therapeutic Strategies. Genes 15(8). https:\/\/doi.org\/10.3390\/genes15081038","DOI":"10.3390\/genes15081038"},{"issue":"11","key":"4437_CR34","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1158\/1078-0432.CCR-23-1880","volume":"30","author":"R Ciccone","year":"2024","unstructured":"Ciccone R, Quintarelli C, Camera A et al (2024) GD2-Targeting CAR T-cell Therapy for Patients with GD2\u00fe Medulloblastoma. Clin Cancer Res 30(11):2545\u20132557. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1880","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4437_CR35","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","volume":"26","author":"J Theruvath","year":"2020","unstructured":"Theruvath J, Sotillo E, Mount CW et al (2020) Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors. Nat Med 26(5):712\u2013719. https:\/\/doi.org\/10.1038\/s41591-020-0821-8","journal-title":"Nat Med"},{"key":"4437_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1145706","volume":"14","author":"P Zuo","year":"2023","unstructured":"Zuo P, Li Y, He C et al (2023) Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas. Front Immunol 14:1145706. https:\/\/doi.org\/10.3389\/fimmu.2023.1145706","journal-title":"Front Immunol"},{"key":"4437_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.817296","volume":"13","author":"YJ Lin","year":"2022","unstructured":"Lin YJ, Mashouf LA, Lim M (2022) CAR T cell therapy in primary brain tumors: current investigations and the future. Front Immunol 13:817296. https:\/\/doi.org\/10.3389\/fimmu.2022.817296","journal-title":"Front Immunol"},{"issue":"5","key":"4437_CR38","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41591-018-0031-9","volume":"24","author":"V Ramaswamy","year":"2018","unstructured":"Ramaswamy V, Taylor MD (2018) CAR T cells for childhood diffuse midline gliomas. Nat Med 24(5):534\u2013535. https:\/\/doi.org\/10.1038\/s41591-018-0031-9","journal-title":"Nat Med"},{"key":"4437_CR39","unstructured":"St. Jude Children\u2019s Research Hospital (2026) Loc3CAR: Locoregional Delivery of B7-H3-Specific Chimeric Antigen Receptor Autologous T Cells for Pediatric Patients With Primary CNS Tumors. clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05835687. Accessed 2 Apr 2026"},{"key":"4437_CR40","unstructured":"Locatelli F (2025) Phase I Study of Anti-GD2 Chimeric Antigen Receptor-Expressing T Cells in Pediatric and Young Adult Patients Affected by Relapsed\/Refractory Central Nervous System Tumors. clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05298995.\u00a0Accessed 2 Apr 2026"},{"key":"4437_CR41","unstructured":"CAR T cells (SC-CAR4BRAIN) for the Treatment of Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, or Recurrent or Refractory Central Nervous System Tumors in Children and Young Adult Patients - NCI. June 23, 2016. https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/v?id=NCI-2023-00874.\u00a0Accessed 2 Apr (2026)"},{"key":"4437_CR42","unstructured":"Chulalongkorn University (2025) Safety and Efficacy of Intraventricular Infusion of B7H3 With IL-7 Receptor Alpha Signaling Chimeric Antigen Receptor T Cell in Diffuse Intrinsic Pontine Glioma. clinicaltrials.gov.\u00a0https:\/\/clinicaltrials.gov\/study\/NCT06221553.\u00a0Accessed 2 Apr 2026"},{"key":"4437_CR43","unstructured":"Stanford University (2026) Phase I Clinical Trial of GPC2 Chimeric Antigen Receptor T (GPC2-CAR T) Cells for Relapsed or Refractory Medulloblastoma in Children and Young Adults. clinicaltrials.gov.\u00a0https:\/\/clinicaltrials.gov\/study\/NCT07087002. Accessed 2 Apr 2026"},{"key":"4437_CR44","unstructured":"City of Hope Medical Center (2026) Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13R\u03b12-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Children With Recurrent\/Refractory Malignant Brain Tumors. clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04510051. Accessed 2 Apr 2026"},{"issue":"7","key":"4437_CR45","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/neuonc\/nov318","volume":"18","author":"R Alkins","year":"2016","unstructured":"Alkins R, Burgess A, Kerbel R, Wels WS, Hynynen K (2016) Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival. Neuro-Oncol 18(7):974\u2013981. https:\/\/doi.org\/10.1093\/neuonc\/nov318","journal-title":"Neuro-Oncol"},{"issue":"1","key":"4437_CR46","doi-asserted-by":"publisher","first-page":"vdad111","DOI":"10.1093\/noajnl\/vdad111","volume":"5","author":"P Martinez","year":"2023","unstructured":"Martinez P, Nault G, Steiner J et al (2023) MRI-guided focused ultrasound blood-brain barrier opening increases drug delivery and efficacy in a diffuse midline glioma mouse model. Neuro-Oncol Adv 5(1):vdad111. https:\/\/doi.org\/10.1093\/noajnl\/vdad111","journal-title":"Neuro-Oncol Adv"},{"issue":"824","key":"4437_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adq6645","volume":"17","author":"CC Wu","year":"2025","unstructured":"Wu CC, Szalontay L, Pouliopoulos AN et al (2025) Blood-brain barrier opening with neuronavigation-guided focused ultrasound in pediatric patients with diffuse midline glioma. Sci Transl Med 17(824):eadq6645. https:\/\/doi.org\/10.1126\/scitranslmed.adq6645","journal-title":"Sci Transl Med"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04437-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-026-04437-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04437-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:32:30Z","timestamp":1786073550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-026-04437-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4437"],"URL":"https:\/\/doi.org\/10.1007\/s10143-026-04437-0","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"1 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This systematic review was conducted and reported in accordance with the PRISMA 2020 statement and with the ethical principles outlined in the Declaration of Helsinki. Because only previously published, aggregate data were used and no identifiable individual level data were collected or analyzed, this work did not constitute human subjects research under the policies of the Rutgers Institutional Review Board.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"519"}}